| Methods |
7‐day washout period; 4‐week single‐blind placebo baseline phase; inclusion criteria= average sitting DBP 95‐115 mm Hg of week 2 and 4 of baseline phase recordings; 6‐week double‐blind treatment |
| Participants |
Enalapril 5 mg: n=56(38 males,18 females); mean age=52.5(11.2) years; baseline SBP=152.8(17.3) mm Hg, DBP=100.5(5.2) mm Hg, HR=77.4(9.2) bpm;
Placebo: n=58(39 males,19 females); mean age=54.2(10.2) years; baseline SBP=152.5(13.0) mm Hg, DBP=100.4(4.8) mm Hg, HR=76.8(10.0) bpm |
| Interventions |
Enalapril 5 mg once daily;
Placebo;
administered in the morning (between 7:30 AM and 10:00 AM) |
| Outcomes |
Adjusted mean change from baseline in SBP/DBP using mercury sphygmomanometer;
Trough sitting SBP/DBP using mercury sphygmomanometer;
HR;
WDAE |
| Notes |
Adjusted BP change reported, SD of change not reported, endpoint BP and SD reported; imputed endpoint SD for SD of change; used endpoint BP and SD data to calculate change in BP instead of entering adjusted BP change data; BP data from Table II, p. 53; Jadad score=4; funding source= Merck |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
